ERBB2 and breast cancer: This evidence is based on very sporadic findings, since HER2 activating mutations are described in less than 2% of BC cases with a higher frequency in HR-positive BCs in comparison to TNBC and likewise in lobular carcinomas than in ductal ones [83].